-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HUDL/RpN+88uYbsCcTKZX++1CeDtoQpwY1ykojAErZWHTpwwulIWZ6RKV3e/09dc stFNGpxanOnHt+ayKPkLDw== 0001181431-09-029528.txt : 20090608 0001181431-09-029528.hdr.sgml : 20090608 20090608165830 ACCESSION NUMBER: 0001181431-09-029528 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20090604 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20090608 DATE AS OF CHANGE: 20090608 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 09880130 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 8-K 1 rrd245339.htm Prepared By R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  06/04/2009
 
Savient Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Commission File Number:  0-15313
 
DE
  
13-3033811
(State or other jurisdiction of
  
(IRS Employer
incorporation)
  
Identification No.)
 
One Tower Center
East Brunswick, NJ 08816
(Address of principal executive offices, including zip code)
 
732-418-9300
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
 
(d) On June 4, 2009, the Board of Directors (the "Board") of Savient Pharmaceuticals, Inc. (the "Company"), based upon the recommendation of the Board's Nominating and Corporate Governance Committee, elected Dr. Ginger Constantine, M.D. to serve on the Company's Board of Directors. In connection with the election, the Board expanded the size of the Board to seven directors. Dr. Constantine will serve for a term expiring at the Company's annual meeting of stockholders in 2010 and until her successor shall have been elected and qualified or until her earlier resignation or removal.

Dr. Constantine, age 54, currently serves as Vice President of Women's Health & Bone Repair Medical Research at Wyeth Research, a division of Wyeth Pharmaceuticals, and has held Vice President positions with Wyeth since 2000.   

There is no agreement or understanding between Dr. Constantine and any other person pursuant to which Dr. Constantine was appointed to the Board. Dr. Constantine is not a party to any tra nsaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Board has appointed Dr. Constantine to serve on its Nominating and Corporate Governance Committee.

Dr. Constantine shall receive compensation for serving on the Board and its committees pursuant to the Board compensation plan that was previously disclosed in the Company's filings with the SEC.

The full text of the press release issued in connection with Dr. Constantine's election to the Board is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 
 
Item 9.01.    Financial Statements and Exhibits
 
(d) Exhibits

See Exhibit Index attached hereto.

 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
      
 
Savient Pharmaceuticals, Inc.
 
 
Date: June 08, 2009
     
By:
 
/s/    Philip K. Yachmetz
               
Philip K. Yachmetz
               
SVP, General Counsel & Secretary
 
 

 

Exhibit Index
 
Exhibit No.
  
Description
EX-99.1
  
Press Release dated June 5, 2009
EX-99.1 2 rrd245339_28644.htm PRESS RELEASE DATED JUNE 5, 2009

Savient Letterhead

 

Contact:

Mary Coleman

Savient Pharmaceuticals, Inc.

information@savient.com

(732) 418-9300

Susan Neath

Burns McClellan

sneath@burnsmc.com

(212) 213-0006

Savient Announces Election of Dr. Ginger D. Constantine to Board of Directors

 

EAST BRUNSWICK, N.J. - (June 5, 2009) - Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Ginger D. Constantine, M.D. has been elected to the Company's Board of Directors. Dr. Constantine currently serves as Vice President of Women's Health & Bone Repair Medical Research at Wyeth Research, a division of Wyeth Pharmaceuticals. Since 1992, Dr. Constantine has held various management positions of increasing responsibility in the therapeutic areas of rheumatology, metabolism and bone repair within the Wyeth Pharmaceuticals and Wyeth Research organizations. Prior to joining Wyeth, Dr. Constantine was a practicing physician specializing in Rheumatology and Internal Medicine and has authored a number of articles, abstracts as well as presentations, in the area of rheumatology and arthritis for peer reviewed publications and meetings.

Dr. Constantine obtained her medical degree from Temple University and completed her Rheumatology Fellowship at the University of Pennsylvania. She is currently a member of the American College of Rheumatology and member of and committee member for The Endocrine Society and is a member of various medical societies including the American Medical Association, American Rheumatism Association and the Pennsylvania Medical Society.

"We are pleased to welcome Dr. Constantine to our Board of Directors," said Stephen Jaeger, Chairman of the Board of Directors. "She has a long and impressive career as a senior executive with Wyeth and extensive expertise in the area of rheumatology, gout and arthritis. Her experience and expertise will be an invaluable addition to the Board and the Company as we enter this final stretch towards approval of KRYSTEXXA™ by the FDA and the evaluation of potential collaborations and strategic alliances for the commercialization and further development of KRYSTEXXA."

 

 

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient's product development candidate, KRYSTEXXA™ (pegloticase) for treatment failure gout has reported positive Phase 1, 2 and 3 clinical data. The KRYSTEXXA Phase 3 clinical studies were completed in October 2007; the BLA was filed with the FDA in October 2008 and the FDA granted priority review status in December 2008. The Company submitted amendments to the BLA to the FDA in January 2009 and the FDA extended the review period by three months, revising the PDUFA date to August 1, 2009. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase®, from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CI II in the U.S. Further information on Savient can be accessed by visiting: http://www.savient.com. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.


SVNT - G

-----END PRIVACY-ENHANCED MESSAGE-----